ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS

INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2021

4.	INTANGIBLE ASSETS

Intangible assets at September 30, 2021 and December 31, 2020 consist of the following:

	September 30, 2021						December 31, 2020
	Cost		Accumulated Amortization		Net		Cost		Accumulated Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100,046	$	2,538,123	$	1,561,923	$	4,100,046	$	2,098,833	$	2,001,213
Rights to intermediates		907,421		561,737		345,684		907,421		464,513		442,908
Customer contract		1,076,557		1,076,557		-		1,076,557		1,076,557		-
	$	6,084,024	$	4,176,417	$	1,907,607	$	6,084,024	$	3,639,903	$	2,444,121

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.2 million for the three months ended September 30, 2021 and 2020, and $0.5 million for the nine months ended September 30, 2021 and 2020. Estimated aggregate future aggregate amortization expense is expected to be as follows:

Remainder of 2021	$	178,838
2022		715,352
2023		715,352
2024		298,065